The significance of itraconazole for treatment of fungal infections of skin, nails and mucous membranes;Stellenwert von itraconazol in der behandlung von pilzinfektionen der haut, nägel und schleimhäute

JDDG - Journal of the German Society of Dermatology

Volumn 7, Issue 1, 2009, Pages 11-19

  Korting, Hans Christian ^a   Schöllmann, Claudia ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Fungal infections; Itraconazole; Skin

Indexed keywords

FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; TERBINAFINE;

ANTIFUNGAL ACTIVITY; DRUG EFFICACY; FINGERNAIL ONYCHOMYCOSIS; HUMAN; MICROSPORUM CANIS; MYCOSIS; NONHUMAN; ONYCHOMYCOSIS; OROPHARYNX CANDIDIASIS; REVIEW; RISK BENEFIT ANALYSIS; SKIN CANDIDIASIS; SKIN INFECTION; TINEA CAPITIS; TINEA CORPORIS; TINEA CRURIS; TINEA MANUUM; TINEA PEDIS; TOENAIL ONYCHOMYCOSIS; VAGINA CANDIDIASIS;

EID: 58149288265     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2008.06751.x     Document Type: Review

References (65)

1. Niewerth M, Korting HC. Management of Onychomycoses. Drugs 1999 58 : 283 296.
2. Haria M, Bryson HM, Goa KL. Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 1996 51 : 585 620.
3. Gupta AK, Kohl Y, Batra R. In vitro activities of posaconazole, ravoconazole, terbinafine, itraconazole and flucona-zole against dermatophyte, yeast and non-dermatophyte species. Med Mycol 2005 43 : 179 185.
4. Gupta AK, Shear NH. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis. Drug Safety 2000 22 : 33 52.
5. Mishra M, Panda P, Tripathy S, Sengupta S, Mishra K. An open randomized comparative study of oral itraconazole pulse and terbinafine pulse in the treatment of onychomycosis. Indian J Dermatol Venereol Leprol 2005 71 : 262 266.
6. Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrijsen K, Woestenborghs R, Van Cutsem J, Cauwenbergh G. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989 32 Suppl 1 : 67 87.
7. Schäfer-Korting M, Korting HC, Rittler W, Obermüller W. Influence of serum proteins on the in vitro activity of anti-fungal agents. Infection 1995 23 : 292 297.
8. Schäfer-Korting M, Korting HC, Amann F, Peuser R, Lukacs A. Influence of albumin on itraconazole and ketokonazole antifungal activity: results of a dynamic in vitro study. Antimicrob Agents Chemother 1991 35 : 2053 2056.
9. Cauwenbergh G, Degreef H, Heykants J, Woestenborghs R, Van Rooy P, Hae-verans K. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988 18 : 263 268.
10. Sobue S, Sekiguchi K, Nabeshima T. Intracutaneous distributions of fluconazole, itraconazole, and griseofulvin in Guinea pigs and binding to human stratum corneum. Antimicrob Agents Chemother 2004 48 : 216 223.
11. Schäfer-Korting M, Korting HC, Lukacs A, Heykants J, Behrendt H. Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. J Am Acad Dermatol 1990 22 : 211 215.
12. Willemsen M, De Doncker P, Willems J, Woestenborghs R, Van de Velde V, Heykants J, Van Cutsem J, Cauwenbergh G, Roseeuw D. Posttreatment itraconazole levels in the nail. New implications for treatment of onychomycosis. J Am Acad Dermatol 1992 26 : 731 735.
13. Morimoto K, Tanuma H, Kikichi I, Kusonoki T, Kawana S. Pharmacokinetic investigation of oral itraconazole in stratum corneum level of tinea pedis. Mycoses 2004 47 : 104 114.
14. De Doncker P. Itraconazole and terbinafine in perspective: from Petri dish to patient. J Eur Acad Dermatol Venereol 1999 12 (Suppl 1 S10 S16.
15. FDA Public Health Advisory. The safety of Sporanox capsules and Lamisil tablets for the treatment of onychomycosis, verfügbar unter http://www.fda.gov/cder/drug/advisory/sporanox-lamisil/advisory.htm.
16. Kämmerer W. Klinisch wichtige Interaktionen vonAntimykotika. Arzneimitteltherapie 2005 23 : 72 79.
17. Seebacher C, Brasch J. Onychomykose. In : Korting HC, Callies R, Reusch M, Schlaeger M, Sterry W (Hrsg Derma-tologische Qualitätssicherung. Leitlinien und Empfehlungen. 5. Auflage. Berlin : ABW Wissenschaftsverlag, 2007 : 136 143.
18. Korting HC, Ollert M, Abeck D and the German Collaborative Dermatophyte Drug Susceptibility Study Group. Results of German multicenter study of antimicrobial susceptibilities of Trichophyton rubrum and Trichophyton mentagrophytes strains causing tinea unguinum. Antimicrob Agents Chemother 1995 39 : 1206 1208.
19. Lecha M, Effendy I, Feuilhade de Chauvin M, Di Chiacchio N, Baran N. Treatment options - development of consensus guidelines. J Europ Acad Dermatol Venereol 2005 19 Suppl 1 : 25 33.
20. Korting HC, Schäfer-Korting M, Zienicke H, Georgii A, Ollert MW. Treatment of tinea unguinum with medium and high doses of ultramicrosize grisefulvin compared with that with itraconazole. Antimicrob Agent Chemother 1993 37 : 2064 2068.
21. ® German Onychomycosis Study Group. Brit J Dermatol 1996 134 : 18 21.
22. Gupta AK, Gregurek-Novak T. Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketokonazole in treatment of Scopulariopsis brevicaulis onychomycosis of the toes. Dermatology 2001 202 : 235 238.
23. De Doncker P, Gupta AK, Marynissen G, Stoffels P, Heremans A. Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. J Am Acad Dermatol 1997 37 : 969 974.
24. Aman S, Akbar TM, Hussain I, Jahangir M, Haroon TS. Itraconazole pulse therapy in the treatment of disto-lateral subungual onychomycosis. J Coll Physicians Surg Pak 2003 13 : 618 620.
25. Kawada A, Aragane Y, Tezuka T. Clinical and pharmacokinetic studies of continous itraconazole for the treatment of onychomycosis. J Dermatol 2004 31 : 104 108.
26. Elewski BE : Onychomycosis. Treatment, quality of life, and economic issues. Am J Clin Dermatol 2000 1 : 19 26.
27. Gupta AK, Ryder JE, Johnson AM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol 2004 150 : 537 544.
28. Cohen AD, Medvesovsky E, Shalev R, Biton A, Chetov T, Naimer S, Shai A, Vardy DA. An independent comparison of terbinafine and itraconazole in the treatment of toenail onychomycosis. J Dermatol Treatm 2003 14 : 237 242.
29. Gupta AK, Gover MD, Lynde CW. Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte onychomycosis in patients with diabetes mellitus. J Eur Acad Dermatol Venereol 2006 20 : 1188 1193.
30. De Backer M, De Keyser P, De Vroey C, Lesaffre E. A 12-week treatment for dermatophyte toe onychomycosis: ter-binafine 250 mg/day vs. itraconazole 200 mg/day - a double-blind comparative trial. Br J Dermatol 1996 46 Suppl 46 : 16 17, 38.
31. Epstein E. How often does oral treatment of toenail onychomycosis produce a disease-free nail? Analysis of published data. Arch Dermatol 1998 134 : 1551 1554.
32. Glyn E, Evans V, Sigurgeirsson B for the LION study group. Double blind, randomized study of continous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. Br Med J 1999 318 : 1031 1035.
33. Sigurgeirsson B, Olaffson JH, Steinsson JP, Paul C, Billstein S, Evans GV. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis. Arch Dermatol 2002 138 : 353 357.
34. Krob AH, Fleischer AB Jr., D'Agostino R Jr., Feldman SR. Terbinafine is more effective than itraconazole in treating toenail onychomycosis: results from a meta-analysis of randomized controlled trials. J Cutan Med Surg 2003 7 : 306 311.
35. Warhaw EM, Nelson D, Carver SM, Zielke GR, Webster N, Lederle FA, Fett DD. A pilot evaluation of pulse itraconazole vs. terbinafine for treatment of Candida toenail onychomycosis. Int J Dermatol 2005 44 : 785 788.
36. Mügge C, Haustein UF, Nenoff P. Onychomykosen - eine retrospektive Untersuchung zum Erregerspektrum. J Dtsch Dermatol Ges 2006 4 : 218 228.
37. Tosti A, Piraccini BM, Stinchi C, Colombo MD. Relapses of onychomycosis after successful treatment with systemic antifungals: a three-year follow-up. Dermatology 1998 197 : 162 166.
38. Seebacher C, Korting HC. Tinea der freien Haut. In : Korting HC, Callies R, Reusch M, Schlaeger M, Sterry W (Hrsg Dermatologische Qualitä tssicherung. Leitlinien und Empfehlungen. 5. Auflage. Berlin : ABW Wissenschaftsverlag, 2007 : 129 135.
39. Bell-Syer SEM, Hart R, Crawford F, Torgerson DJ, Russel I. Oral treatment for fungal infections of the skin of the foot. Cochrane Database Syst Rev 2004 3 : p: CD003584.
40. Parent D, Decroix J, Heen M. Clinical experience with short schedules of itraconazole in the treatment of tinea corporis. Dermatology 1994 189 : 378 381.
41. De Keyser P, De Backer M, Massart DL, Wesetlinck KJ. Two-week oral treatment of tinea pedis, comparing terbinafin (250 mg/day) with itraconazole (100 mg/day): a double-blind, multicentre study. Br J Dermatol 1994 130 Suppl 43 : 22 25.
42. Lospalluti M, Barile F, Pantaleo AK, Conese M, Guerra AP, Lo Re M, D'Amico G, Barbieri G. Comparative evaluation of fluconazole 50 mg and 100 mg versus itraconazole 100 mg in the treatment of dermatomycoses. Clin Ter 1994 : 144 : 129 138.
43. Schuller J, Remme JJ, Rampen FH, Van Neer FC. Itraconazole in the treatment of tinea pedis and tinea manuum: comparison of two treatment schedules. Mycoses 1998 41 : 515 520.
44. Hoharitanon S, Chaichalotornkul J, Sindhupak W. A comparison of the efficacy between two itraconazole generic products and the innovative itraconazole in the treatment of tinea pedis. J Med Assoc Thai 2005 88 Suppl 4 : S167 172.
45. Seebacher C, Abeck D. Tinea capitis. In : Korting HC, Callies R, Reusch M, Schlaeger M, Sterry W (Hrsg Derma-tologische Qualitätssicherung. Leitlinien und Empfehlungen. 5. Auflage. Berlin : ABW Wissenschaftsverlag, 2007 : 144 153.
46. Tietz HJ, Czaika V, Ulbricht HM, Sterry W. Tinea capitis in Germany. A survey in 1998. Mycoses 1999 42 Suppl 2 : 73 76.
47. Lopez-Gomez S, Del Palacio A, Van Cutsem J, Soledad Cuetara M, Iglesias L, Rodriguez-Noriega A. Itraconazole versus griseofulvin in the treatment of tinea capitis: a double-blind randomized study in children. Int J Dermatol 1994 33 : 743 747.
48. Gupta AK, Adam P, Dlova N, Lynde CW, Hofstader S, Morar N, Aboobaker J, Summerbell RC. Therapeutic options for the treatment of tinea capitis caused by Trichophyton species: griseo-fulvin versus the new oral antifungal agents, terbinafine, itraconazole, and fluconazole. Pediatr Dermatol 2001 18 : 433 438.
49. Möhrenschläger M, Korting HC, Seidl HP, Ring J, Abeck D. Tinea capitis. Therapieoptionen im Post-Griseofulvin-Zeitalter. Hautarzt 2002 53 : 788 794.
50. Gupta AK, Ginter G. Itraconazole is effective in the treatment of tinea capitis caused by Microsporum canis. Pediatr Dermatol 2001 18 : 519 522.
51. Ginter-Hanselmayer G, Smoll J, Gupta A. Itraconazole in the treatment of tinea capitis caused by Microsporum canis: experience in a large cohort. Pediatr Dermatol 2004 21 : 499 502.
52. Reinel D, Plettenberg A. Orale Candidose. In : Korting HC, Callies R, Reusch M, Schlaeger M, Sterry W (Hrsg Dermatologische Qualitätssicherung. Leitlinien und Empfehlungen. 5. Auflage. Berlin : ABW Wissenschaftsverlag, 2007 : 167 170.
53. Oude Lasho AM, De Bock R, Herbrecht R, De Pauw BE, Krcmery V, Aoun M, Akova M, Cohen J, Siffnerova H, Egyed M, Ellis M, Marinus A, Sylvester R, Kullberg BJ, EORTC Invasive Fungal Infections Group. An open multi-centre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis. Eur J Cancer 2004 40 : 1314 1319.
54. Patton LL, Bonito AJ, Shugars DA. A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001 92 : 170 179.
55. Pienaar ED, Young T, Holmes H. Interventions for the prevention and management of oropharyngeal candidasis associated with HIV infection in adults and children. Cochrane Database Syst Rev 2006 3 : p. CD003940.
56. Seebacher C. Candidose der Haut. In : Korting HC, Callies R, Reusch M, Schlaeger M, Sterry W (Hrsg Derma-tologische Qualitätssicherung. Leitlinien und Empfehlungen. 5. Auflage. Berlin : ABW Wissenschaftsverlag, 2007 : 160 166.
57. Kirkpatrick CH. Chronic mucocutaneous candidiasis. In : Bodey GP (Hrsg Candidiasis, Pathogenesis, Diagnosis, and Treatment. Raven Press, New York. S. 167 184. Zitiert nach: Seebacher C. Candidose der Haut. In: Korting HC, Callies R, Reusch M, Schlaeger M, Sterry W (Hrsg): Dermatologische Qualitä tssicherung. Leitlinien und Empfeh-lungen. 5. Auflage. Berlin: ABW Wissenschaftsverlag, 2007: 160-166.
58. Del Rosso JQ, Zellis S, Gupta AK. Itraconazole in the treatment of superficial cutaneaous and mucosal Candida infections. J Am Osteopath Assoc 1998 98 : 497 502.
59. Mendling W, Seebacher C. Vulvova-ginalkandidose. In : Korting HC, Callies R, Reusch M, Schlaeger M, Sterry W (Hrsg Dermatologische Qualitä tssicherung. Leitlinien und Empfeh-lungen. 5. Auflage. Berlin : ABW Wissenschaftsverlag, 2007 : 154 159.
60. Friese K, Mendling W. Therapie der vaginalen Mykosen - oral vs. lokal. Gynäkologe 1996 29 : 221 228. Zitiert nach: Mendling W, Seebacher C. Vulvovaginalkandidose. In: Korting HC, Callies R, Reusch M, Schlaeger M, Sterry W (Hrsg): Dermatologische Qualitätssicherung. Leitlinien und Empfehlungen. 5. Auflage. Berlin: ABW Wissenschaftsverlag, 2007: 154-159.
61. Chattopadhyay S. Itraconazole: better choice to treat recurrent vulvovaginal candidoses. J Indian Med Assoc 2004 102 : 523. Zitiert nach: Mendling W, Seebacher C. Vulvovaginalkandidose. In: Korting HC, Callies R, Reusch M, Schlaeger M, Sterry W (Hrsg): Dermatologische Qualitätssicherung. Leitlinien und Empfehlungen. 5. Auflage. Berlin: ABW Wissenschaftsverlag, 2007: 154-159.
62. Spacek J, Buchta V. Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1-day and a 3-day regimen. Mycoses 2005 48 : 165 171.
63. Urunsak M, Ilkit M, Evruke C, Urunsak I. Clinical and mycological efficacy of single-day treatment with itraconazole (400mg) in acute vulvovaginal candidosis. Mycoses 2004 47 : 422 427.
64. Fehrabas A, Koc AN, Uksal U, Aygen E, Mistik S, Yildiz S. Terbinafine versus itraconazole and fluconazole in the treatment of vulvovaginal candidiasis. Am J Ther 2006 13 : 332 336.
65. De Punzio C, Garutti P, Mollica G, Nappi C, Piccoli R, Genazzani AR. Fluconazole 150 mg single dose versus itraconazole 200 mg per day for 3 days in the treatment of acute vaginal candidiasis: a double-blind randomized study. Eur J Obstet Gynecol Reprod Biol 2003 106 : 193 197.